These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 25494575)
1. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575 [TBL] [Abstract][Full Text] [Related]
2. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Galvano A; Guarini A; Iacono F; Castiglia M; Rizzo S; Tarantini L; Gori S; Novo G; Bazan V; Russo A Expert Opin Drug Saf; 2019 Jun; 18(6):485-496. PubMed ID: 31062991 [TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. Yang B; Papoian T J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481 [TBL] [Abstract][Full Text] [Related]
7. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eskens FA; Verweij J Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419 [TBL] [Abstract][Full Text] [Related]
8. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469 [TBL] [Abstract][Full Text] [Related]
9. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]. Mross K Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270 [No Abstract] [Full Text] [Related]
10. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Dasanu CA; Padmanabhan P; Clark BA; Do C Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002 [TBL] [Abstract][Full Text] [Related]
11. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors. Kircher SM; Nimeiri HS; Benson AB Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596 [TBL] [Abstract][Full Text] [Related]
13. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843 [TBL] [Abstract][Full Text] [Related]
14. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis. Chen YC; Chen JH; Hsieh FI J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373 [TBL] [Abstract][Full Text] [Related]